14. Detailed 'Summary of findings' table: anterior approach vs conventional approach.
| Outcomes | Illustrative comparative risks* (95% CrI) | Relative effect (95% CrI) | No of participants (studies) | Quality of the evidence (GRADE) | |
| Assumed risk | Corresponding risk | ||||
| Control | Intervention | ||||
| Mortality (perioperative) | 76 per 1000 | 19 per 1000 (2 to 82) | OR 0.23 (0.03 to 1.08) | 185 (2 studies) | ⊕⊝⊝⊝ Very low1,2,3 |
| Mortality (longest follow‐up) | None of the trials reported this outcome. | ||||
| Serious adverse events (proportion) | 125 per 1000 | 154 per 1000 (40 to 457) | OR 1.27 (0.29 to 5.89) | 65 (1 study) | ⊕⊝⊝⊝ Very low1,2,3 |
| Serious adverse events (number) | None of the trials reported this outcome. | ||||
| Health‐related quality of life (30 days, 3 months) | None of the trials reported this outcome. | ||||
| Health‐related quality of life (maximal follow‐up) | None of the trials reported this outcome. | ||||
| *The basis for the assumed risk is the mean control group proportion. The corresponding risk (and its 95% credible interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CrI). Network meta‐analysis was not performed for any of the outcomes since there were only two treatments. CrI: credible intervals; OR: odds ratio. | |||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | |||||
1 Risk of bias was unclear or high in the trial(s) (downgraded by 1 point). 2 Sample size was low (total number of participants fewer than 400 for continuous outcomes and fewer than 300 events in total in both groups for other outcomes) (downgraded by 1 point). 3 Credible intervals spanned no effect and clinically significant effect (20% relative risk reduction for binary outcomes; standardised mean difference of 0.5 for health‐related quality of life) (downgraded by 1 point).